# A 6-week Study to Evaluate the Efficacy and Safety of Lurasidone HCL in Acutely Psychotic Patients With Schizophrenia

> **NCT03465787** · PHASE3 · COMPLETED · sponsor: **Bukwang Pharmaceutical** · enrollment: 210 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** Lurasidone HCL 160 mg
- **DRUG:** Quetiapine XR 600 mg

## Key facts

- **NCT ID:** NCT03465787
- **Lead sponsor:** Bukwang Pharmaceutical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-04-09
- **Primary completion:** 2022-10-26
- **Final completion:** 2022-10-26
- **Target enrollment:** 210 (ACTUAL)
- **Last updated:** 2023-02-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03465787

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03465787, "A 6-week Study to Evaluate the Efficacy and Safety of Lurasidone HCL in Acutely Psychotic Patients With Schizophrenia". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03465787. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*